Received Sep 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | cx4hl | IM |
patient received Boostrix instead of DTaP; inappropriate age; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a 1-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number cx4hl, expiry date 09-NOV-2026) for prophylaxis. Co-suspect products included DTPa (DTaP vaccine) for prophylaxis. On 21-JUL-2025, the patient received Boostrix (intramuscular) .5 ml. On an unknown date, the patient did not receive DTaP vaccine. On 21-JUL-2025, an unknown time after receiving Boostrix, the patient experienced wrong vaccine administered (Verbatim: patient received Boostrix instead of DTaP) and inappropriate age at vaccine administration (Verbatim: inappropriate age). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-AUG-2025 The patient did not have any other conditions and did not receive any other products. The patient received a dose of Tdap (Boostrix) when DTaP should have been administered (medication error or inappropriate age), which led to wrong vaccine administered and inappropriate age at vaccine administration. No further information was provided or obtained.